Important Disclaimer

The reports posted on this site have been written by MBA students at Yale's School of Management in partial fulfillment of their course requirements. The reports are student not professional, they are intended to serve solely as examples of student work at Yale’s School of Management. They are not intended as investment advice. They are based on publicly available information and may not be a complete analyses of all relevant data.

If you use these reports for any purpose, you do so at your own risk. YALE UNIVERSITY, YALE SCHOOL OF MANAGEMENT, AND YALE UNIVERSITY’S OFFICERS, FELLOWS, FACULTY, STAFF, AND STUDENTS MAKE NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, ABOUT THE ACCURACY OR SUITABILITY FOR ANY USE OF THESE REPORTS, AND EXPRESSLY DISCLAIM RESPONSIBIITY FOR ANY LOSS OR DAMAGE, DIRECT OR INDIRECT, CAUSED BY USE OF OR RELIANCE ON THESE REPORTS.

Sort By:

Generic Pharmaceuticals Download
Student Authors:
Ellen Hui and Adindu Nwachku and Liang True Mah and Nell Wen
Report Type:
Industry
Date Posted:
2002-10-21
Report Date:
2002-09-30
Downloads:
4376
Company Discussed Ticker Symbol Return From Company Return SP500 Return
Barr Lab BRL 2002-10-01 to 2003-10-01 0% 20.1%
IVAX Corp. IVX 2002-10-01 to 2003-10-01 -26.7% 20.1%
Mylan Laboratories MYL 2002-10-01 to 2003-10-01 78.1% 20.1%
Phamaceutical Resources PRX 2002-10-01 to 2003-10-01 144.7% 20.1%
Teva Pharmaceutical TEVA 2002-10-01 to 2003-10-01 70.8% 20.1%
Watson Pharmaceutical WPI 2002-10-01 to 2003-10-01 39.1% 20.1%
Recommendation: Strong Buy